Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Recruiting now Phase 4 NCT06057402
Run by Pfizer · for 18 and older · All sexes
What this study is about
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must agree to follow the reproductive criteria as outlined in the protocol
- Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
🚫 You may not be able to join if…
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Where this trial is running
- UCI Health - Irvine Infusion Pharmacy ACC, Irvine, California, United States
- UC Irvine Health, Orange, California, United States
- UCI Health, Orange, California, United States
- UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
- UCHealth Harmony, Fort Collins, Colorado, United States
- UCHealth Greeley Hospital, Greeley, Colorado, United States
- Longs Peak Hospital, Longmont, Colorado, United States
- UCHealth Longs Peak Medical Center, Longmont, Colorado, United States
- UCHealth - Medical Center of the Rockies, Loveland, Colorado, United States
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables, Florida, United States
- University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
+ 21 more sites.
Who to contact
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06057402.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.